Astel­las flesh­es out more PhI­II da­ta for Claudin 18.2 drug

Just weeks af­ter un­veil­ing the first de­tailed late-stage da­ta on its CLDN18.2 drug, Astel­las is beef­ing up the da­ta pack­age with re­sults from a sec­ond Phase III tri­al.

We al­ready knew that adding Astel­las’ zol­be­tux­imab to a chemother­a­py reg­i­men called CAPOX spurred a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in pro­gres­sion-free sur­vival for stom­ach can­cer pa­tients, but the com­pa­ny is now spec­i­fy­ing by how much. The com­bi­na­tion of zol­be­tux­imab plus CAPOX (a reg­i­men that in­cludes capecitabine and ox­ali­platin) re­duced the risk of pro­gres­sion or death by 31.3% (p=0.0007), meet­ing the pri­ma­ry end­point.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN